Ann: Cleansing Notice and Appendix 3B, page-8

Boehringer Ingelheim is clearly an appropriate choice for consulting services.
MacroGenics to receive $9M from Boehringer Ingelheim in preclinical antibody pact

“MacroGenics will receive a $5 million milestone payment, and Boehringer Ingelheim will make a research maintenance payment of $4 million to the antibody developer in the fourth quarter of 2013.”
http://www.fiercebiotechresearch.co...ngelheim-preclinical-antibody-pact/2013-11-11

Xencor Receives Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement
“Xencor, Inc. announced today that the Company received a milestone payment from Boehringer Ingelheim. The payment was triggered by the regulatory submission for Phase 1 clinical trials of a novel monoclonal antibody…. The amount of the milestone payment was not disclosed.”
http://www.fiercebiotech.com/press-...nger-ingelheim-under-antibody-technology-lice

4-Antibody announces long-term collaboration with Boehringer Ingelheim with a maximum value of EUR 177.5m (CHF 266m) for 4-Antibody
“4-Antibody AG will receive payments of up to EUR 177.5 million (CHF 266 million) including upfront and milestone payments from Boehringer Ingelheim upon achievement of certain clinical development milestones”
http://www.adventls.com/life-scienc...um-value-of-eur-1775m-chf-266m-for-4-antibody

F-star achieves milestone in collaboration with Boehringer Ingelheim
“F-star is eligible to receive up to €180 million in total milestone payments for this programme”
http://www.f-star.com/pdf/news/(2014.01.09)F-star BI milestone.pdf